The addition of combination therapies to an oral hypoglycemic agent(s) or insulin is known to generally increase the risk of hypoglycemia; however, multiple meta-analyses including patients with type 1 DM and with no restrictions in races/ethnicities revealed that even dual combination therapy with a SGLT2 inhibitor and insulin did not increase the risk of hypoglycemia over that with a placebo2,3,37. This evidence concerns the gene SLC5A2 and Hypoglycemia.